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Abstract
Antibiotic resistance is one of the biggest threats to human health of our
time. We are being warned of a so-called post-antibiotic era, where a
simple surgery or bacterial infection could kill human beings. Without the
rapid development of novel antibiotics, the continued growth of antibiotic
resistance will put our society in a crisis of unprecedented scale.
The bacterial cell wall resembles a protective barrier and is crucial for
bacterial survival. Hence, disruption of the cell wall synthesis will lead to
cell death. The bacterial membrane protein MraY is involved in the pep-
tidoglycan synthesis, which is a component of the bacterial cell wall, by
catalysing the synthesis of lipid I - a peptidoglycan precursor. In this thesis,
functional and structural studies of MraY with inhibitors were performed
with the future aim of designing novel antibiotics. We solved the crystal
structure of MraY from the Gram-positive pathogen Clostridium bolteae
in complex with the natural product inhibitor tunicamycin at 2.6 Å reso-
lution and provided a biophysical characterisation of the binding mode of
tunicamycin. A structural comparison between MraY and its human ho-
molgue GPT identified regions to modify tunicamycin to selectively target
MraY. We modified and purified tunicamycins to explore their inhibitory
effect and potency towards MraY and identified potent MraY inhibitors
with reduced eukaryotic toxicity. Finally, we optimised the purification pro-
tocol for MraY for future biophysical and structural studies and developed
a novel method using teabags for membrane protein purification.
iii

Acknowledgements
Working on this project was more than challenging and forced me to
push my boundaries. The topic is truly urgent, and - if unaddressed - could
lead to a crisis of unprecedented scale. It is up to all of us to change the
way we use antibiotics in our society. I hope that my work can contribute
to the fight against the ongoing growth of antibiotic resistance.
To my supervisors Gisela and Margareta: I am very grateful that I had
the opportunity to work with you on this challenging project and I thank
you both for your support throughout this thesis. Thanks Gisela, for shar-
ing your knowledge and expertise. Thanks Maggan, for your eye for details
and for always supporting me.
Arjan, it was a pleasure working with you. I am so grateful for all
discussions, helpful advice and support throughout this thesis. It was an
honor being your lab-bench neighbour!
To Per-Olof: You have helped me so much during my thesis with your
in-depth knowledge of NMR; thank you for helping me with performing
the NMR experiments and for all your advice and your kind-heartedness.
I would like to thank all co-authors and collaborators, it was a pleasure
to work with all of you!
To the Structure and Biophysics team at AZ: I thank every single one
of you for your support during my PhD. It was a great time and I will miss
all of you! Thank you for all lunch breaks, fikas and after-works!
I also thank the entire protein team for creating such a great atmosphere
in the lab and for your support!
v
An meine Familie: Mama, Thorsten und Vera - vielen Dank fuer eure Un-
terstuetzung in dieser schweren Zeit, ohne euch wäre diese Arbeit niemals
möglich gewesen!
Emil, I am so grateful that I made the decision to come to Sweden -
meeting you was the best thing that has ever happened to me. You have
supported me during my PhD in so many ways that there are no possible
words to express how grateful I am. I am glad that the PhD is finally over
and I am looking forward to begin our next chapter in life together! Jag
älskar dig!
vi
Publications
This thesis consists of the following research papers:
PAPER I: J.K. Hakulinen, J. Hering, G. Brändén, H. Chen, A. Sni-
jder, M. Ek, and P. Johansson. "MraY–antibiotic com-
plex reveals details of tunicamycin mode of action" Nature
Chemical Biology vol. 13, no. 3, pp. 265–267, Mar. 2017.
PAPER II: J. Hering, E. Dunevall, M. Ek, and G. Brändén, “Struc-
tural basis for selective inhibition of antibacterial target
MraY, a membrane-bound enzyme involved in peptidogly-
can synthesis” Drug Discovery Today, vol. 23, no. 7, pp.
1426–1435, Jul. 2018.
PAPER III: J. Hering*, E. Dunevall*, A. Snijder, M.A. Jackson, T.M.
Hartman, N.P.J. Price, G. Brändén and M. Ek.*These au-
thors contributed equally “Inhibition of the antibacterial
target MraY by modified tunicamycins” Manuscript, 2019
(submitted).
PAPER IV: J. Hering*, J. Winkel Missel*, M. Castaldo, M. Ek, P.
Gourdon, and A. Snijder. *These authors contributed equally
“The rapid ‘teabag’ method for high-end purification of
membrane proteins” Manuscript, 2019.
vii

Contribution report
PAPER I: I expressed the wild-type and mutant proteins and prepared
the membranes for the activity data. I planned, performed,
analysed and interpreted the activity measurements and
prepared the respective figures.
PAPER II: I took part in the design of the study, performed the lit-
erature research, analysed and interpreted the data and
performed the structural alignment and superimposition. I
played a major role in writing the manuscript and preparing
the figures.
PAPER III: I established the purification protocol, prepared the mem-
brane fractions and produced the protein. I planned, per-
formed, analysed and interpreted all experiments and es-
tablished the assays. I took part in writing the manuscript
and preparing the figures.
PAPER IV: I established the teabag protocol for purification of CbMraY,
produced the protein and planned, performed, analysed
and interpreted all experiments with MraY. I took main
responsibility for writing the manuscript.
ix

Abbreviations
Here follows a list and short explanation of the different abbreviations
used in this thesis.
CbMraY Clostridium bolteae MraY
CMC Critical micelle concentration
DDM n-Dodecyl β-D-maltoside
DM n-Decyl β-D-maltoside
FRET Fluorescence resonance energy transfer
GlcNAc N-Acetylglucosamine
GPT GlcNAc-1-P transferase
IMAC Immobilized metal affinity chromatography
IPTG Isopropyl β-D-1-thiogalactopyranoside
ITC Isothermal titration calorimetry
MD2 Muraymycin D2
MraY MurNAc-1-P-transferase
MurNAc N-Acetylmuramic acid
PDB Protein Data Bank
PNPT Polyprenyl-phosphate N-acetylhexosamine 1-
phosphate-transferases
QVM Quinovosamycin
SEC Size exclusion chromatography
Tun Tunicamycin
xi

Contents
Acknowledgements v
Abbreviations xi
1 Introduction 1
1.1 Antibiotic resistance - the curse of modern society . . . . 1
1.2 Antibiotics . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 Classification . . . . . . . . . . . . . . . . . . . . 2
1.2.2 Antibacterial agents - mode of action . . . . . . . 3
1.2.3 Antibiotic resistance - mechanisms and development 4
1.3 Bacterial cell wall . . . . . . . . . . . . . . . . . . . . . 5
1.4 Biological membranes and membrane proteins . . . . . . 7
1.5 MraY and the PNPT superfamily . . . . . . . . . . . . . 10
1.6 Tunicamycin . . . . . . . . . . . . . . . . . . . . . . . . 12
1.7 Structure-based drug design . . . . . . . . . . . . . . . . 14
1.8 Scope of this thesis . . . . . . . . . . . . . . . . . . . . 15
2 Methodology 17
2.1 Expression and purification . . . . . . . . . . . . . . . . 17
2.1.1 Expression of CbMraY . . . . . . . . . . . . . . . 20
2.1.2 Preparation of membranes containing overexpressed
CbMraY for inhibition measurements. . . . . . . 20
2.1.3 Purification of CbMraY . . . . . . . . . . . . . . 22
2.2 Functional studies of CbMraY and ligand interactions . . 22
2.2.1 Enzymatic activity assay . . . . . . . . . . . . . . 22
2.2.2 Inhibition measurements . . . . . . . . . . . . . . 24
2.2.3 Isothermal Titration Calorimetry . . . . . . . . . 25
2.2.4 Water-LOGSY NMR . . . . . . . . . . . . . . . . 26
2.2.5 Thermal stability of MraY . . . . . . . . . . . . . 27
xiii
2.3 Protein-ligand docking . . . . . . . . . . . . . . . . . . . 28
2.4 Protein Crystallisation . . . . . . . . . . . . . . . . . . . 28
3 Structure-based drug discovery applied to CbMraY 31
3.1 The crystal structure of CbMraY . . . . . . . . . . . . . 31
3.1.1 Active site geometry . . . . . . . . . . . . . . . . 34
3.1.2 Enzymatic activity of CbMraY . . . . . . . . . . 35
3.1.3 Mutations to probe the active site . . . . . . . . 36
3.1.4 Binding modes of the natural product inhibitors . 37
3.2 Novel and optimised protocols for purification of mem-
brane proteins . . . . . . . . . . . . . . . . . . . . . . . 39
3.2.1 Optimisation of CbMraY expression, purification
and crystallisation . . . . . . . . . . . . . . . . . 39
3.2.2 A new protocol for improved membrane protein pu-
rification using teabags . . . . . . . . . . . . . . 40
3.3 Cross-reactivity with human GPT . . . . . . . . . . . . . 41
3.3.1 Structural comparison of MraY and GPT . . . . . 42
3.3.2 Active site comparison . . . . . . . . . . . . . . . 42
3.3.3 Comparison of tunicamycin interactions . . . . . 45
3.4 Biophysical characterisation of tunicamycin binding . . . 46
3.4.1 Modified tunicamycin analogues and their binding
to MraY . . . . . . . . . . . . . . . . . . . . . . 46
3.5 Rationalisation of selective MraY inhibitors . . . . . . . . 53
4 Concluding remarks 57
Bibliography 59
xiv
Chapter 1
Introduction
1.1 Antibiotic resistance - the curse of modern
society
Growing up in our modern society gives the impression of infinite security
and stability. Strangely enough, the world as we know it with all its comfort
and medical innovation has arisen not a long time ago. The dark times are
long forgotten and seem ancient, but are not much older than a century.
The invention of synthetic antibacterial agents and the finding of peni-
cillin at the beginning of the 20th century have dramatically changed
human civilisation by saving millions of lives [1]. Infectious diseases were
thought to be eradicated soon, thanks to the powerful antibiotic drugs.
The inventor of penicillin, Alexander Fleming, was the first to predict the
rise of possible resistance due to improper usage of the drugs. The golden
era of antibiotics occurred in the middle of the 20th century, when the de-
mand for antibiotics in several sectors increased, hence reducing its price.
The first cases of antibiotic resistance were detected shortly after the in-
troduction of novel agents to the market. The boom of antibiotics and
the finding of new compounds slowly lessened over the coming decades,
and no novel antibiotic agents have been developed since the 1980s [2].
Simultaneously, antibiotic resistance has accelerated dramatically and is
now considered a major threat to human health and society [1].
The increase of multidrug-resistant bacteria is a clear warning sign. The
focus of antibiotic research now only lies in the modification of already
1
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existing drugs. The most significant contributors responsible for the advent
of resistant bacterial strains is the consistent misuse of antibiotics - both
clinically as well as in agriculture - and sadly enough, the still insufficient
knowledge and education about its correct use [3]. Another driving factor
is the use of the same or similar antibacterial agents in agriculture as in
clinical use, which can favour the spread of resistance between animal
and human populations. The use of antibiotics in cattle feed as a growth
promoter is yet another example of the irresponsible use of antibiotics [4].
Antibiotic-resistant bacteria are justly named superbugs as they have
become a severe threat to human health by causing life-threatening in-
fections. In Europe alone, every year, an estimated 25.000 people die
of infections caused by multiple drug resistance (MDR) bacteria and
methicillin-resistant Staphylococcus aureus (MRSA) are spreading rapidly
worldwide [3]. As a matter of fact, the World Health Organization (WHO)
is warning of a post-antibiotic era, resulting in more frequent infections
that become impossible to treat leading us to a future that might seem
very similar to the ancient times, where small injuries and any simple
surgery can end deadly [5].
1.2 Antibiotics
1.2.1 Classification
Antibiotics are a type of antimicrobial agents, which are used effectively
to treat bacterial infections. Antibiotics can, in general, be classified based
on
• the chemical structure
• the action
• the activity
• and the spectrum
of the antibacterial compound. The chemical structure will give informa-
tion on the chemical composition of the drug while the action describes
2
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the respective targets of the compound. The activity distinguishes between
bactericidal or bacteriostatic compounds. A bactericidal agent can kill the
bacteria, whereas a bacteriostatic compound inhibits bacterial growth [6].
In the latter case, the immune system of the patient will have to be able
to kill the bacteria. Finally, the spectrum distinguishes between narrow
or broad-spectrum compounds: broad-spectrum antibacterial agents are
active against a variety of bacterial species and therefore, may be used
to treat different infectious diseases, whereas narrow-spectrum antibiotics
are active against a specific type of bacteria [7].
1.2.2 Antibacterial agents - mode of action
The mode of action describes how the respective antibacterial compounds
take action and how they function. The next paragraph will give an
overview of the existing targets (illustrated in Figure 1.1)
Figure 1.1: Mode of action of antibacterial agents. Simplified schematic of the
mode of action of antibiotics illustrating the antibacterial targets of a bacterial
cell. The illustration is inspired by [8].
3
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The most common antibiotics act via addressing the bacterial cell wall.
Inhibition of the cell wall synthesis will consequently lead to cell disrup-
tion and cell death. Other compounds can target the outer cell membrane.
These drugs are selective to Gram-negative bacteria and disrupt osmotic
integrity. Another way is to act via DNA replication. A possible target
would be the topoisomerase, which is a protein that is involved in main-
taining the DNA structure. Inhibition of the topoisomerase would lead to
cell death as the cells would not be able to replicate. Anti-metabolites-
such as folic acid - is another possible target for antibiotics: known in-
hibitors act by mimicking the substrates of the folic acid synthesis. The
last class of target is RNA and protein synthesis. Here the compounds can
act either on the nucleotides, on the RNA polymerase or via ribosomal
binding [8, 9].
As the number of targets is limited, drug development of antibiotics
is narrowed on these few options and focuses on the development of new
antibiotics or the modification of existing agents.
1.2.3 Antibiotic resistance - mechanisms and development
Life-threatening infections caused by bacteria that have developed resis-
tance to common antibiotics have become a serious health issue. Those
infections are more severe, require more complex treatment and are sig-
nificantly more expensive. To date, bacteria have become resistant to all
classes of antibiotics that are available on the market [3].
The molecular basis for developing resistance to antibiotics is complex
and can occur in different ways. Recently, new mechanisms have led to
the simultaneous development of resistance to several classes of antibi-
otics resulting in the dangerous MDR bacterial strains [10]. As antibiotics
have the potential to kill bacteria, the latter follow a natural process that
stimulates the resistance. Hence, the antibacterial agents induce selective
pressure, and the resistance occurs via mutations. In general, mutations
leading to resistance can happen spontaneously. However, the most com-
mon type of resistance is acquired and occurs via horizontal gene transfer
and conjugation of plasmid DNA. In this example, a circular DNA molecule
(plasmid) encodes for the antibiotic resistance gene that is transferrable
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to other bacterial cells via conjugation. Other types of horizontal gene
transfer can occur via transformation - this requires the bacterial cells to
be competent, which means they are temporarily more permeable and can
take up external DNA - and via transduction - certain types of viruses,
so-called macrophages, infect bacteria and with this inject DNA material
into the bacterial cells [1].
The acquired development of resistance can also happen endogenously
via mutations of chromosomal bacterial DNA. The resistance gene is then
transferred vertically to the respective daughter cells.
There are three basic types for the acquired development of resistance:
1. Reduced intracellular accumulation of the drug via reduced or in-
creased influx or efflux of the drug.
2. Enzymatic inactivation of the drug.
3. Modification of the cellular target via
• mutation
• chemical modification
• the protection of the target site or overexpression of a sensitive
target for a more resistant one [6].
It is noteworthy to mention that there is also intrinsic, naturally occurring
resistance in some bacteria due to structural and functional attributes,
which occurs for all members of the bacterial group, e. g. species or genus
and can result in the inaccessibility of a drug through the bacterial cell
wall [6].
1.3 Bacterial cell wall
The differences in bacterial cell wall structures and the resulting response
in the Gram-staining method separated bacteria into two main groups [11].
The cells of Gram-positive and Gram-negative bacteria are composed of
5
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cell wall peptidoglycans that give bacteria their characteristic shape and
viability and are exclusive in prokaryotes. The peptidoglycans are com-
posed of a glycan backbone made of N-acetylated muramic acid and N-
acetylated glucosamine. Furthermore, there are highly cross-linked peptide
chains in Gram-positive and partially cross-linked peptide chains in Gram-
negative bacteria [12].
In Gram-negative bacteria, the cell wall comprises an inner and outer
cell membrane that are separated by the periplasm, containing a thin
peptidoglycan layer. The presence of an outer membrane is characteristic
for Gram-negative bacteria. It contains lipopolysaccharides as a major
component of the outer membrane, which is essential for the integrity
of the permeability. A capsule polysaccharide (CPS) layer often covers
Gram-negative bacteria, and teichoic acids are present in some cases [13].
The peptidoglycan layer in Gram-positive bacteria is substantially thicker
compared to Gram-negative bacteria, and they lack an outer membrane.
The cell wall of Gram-positive bacteria contains polymers, which are often
cross-linked to the peptidoglycan (wall teichoic acids (WTAs)) or can be
attached to the cell membrane as lipoteichoic acids (LTAs) [12,14].
Due to their lack of an outer membrane, Gram-positive bacteria show
in general a good permeability for exogenous substances. In contrast, the
permeability of the outer membrane of Gram-negative bacteria is low, but
pores incorporated to the membrane can regulate the influx.
Mycobacteria and actinobacteria are neither classified as Gram-positive
or Gram-negative bacteria due to their unique cell wall composition. The
presence of arabinogalactan (AG) - attached to the peptidoglycans and
further attached to α-alkyl--hydroxymycolic acids, resulting in a mycolyl-
AG-peptidoglycan complex - is characteristic for these bacteria. The com-
plex acts as a permeability barrier leading to natural antibiotic resistance.
An outer layer consisting of mycolic acids can relate to the outer mem-
brane of Gram-negative bacteria, even though they share no structural
similarity [15].
6
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There are even entirely wall-less bacteria that lack the peptidoglycan
layer and are only composed of a cell membrane [16]. As a result of the
differences in the cell walls, different antibiotic agents target either Gram-
positive or Gram-negative bacteria, Mycobacteria or actinobacteria.
Peptidoglycan synthesis The peptidoglycan, also called murein, is a
rigid structure, giving bacteria their cell shape and protection as well as
resistance to internal osmotic turgor. The primary chemical composition
of peptidoglycan is the same between different genera and consists of par-
allel strands of linked β-(1-4) disaccharide of N-acetylglucosamine (Glc-
NAc) and N-acetylmuramic acid (MurNAc). Peptide strands, connected
to MurNAc residues, periodically cross-link the parallel strands - result-
ing in a 3-dimensional mesh-like structure. The peptidoglycan synthesis
(illustrated in Figure 1.2) initiates in the cytoplasm with the synthesis
of the nucleotide precursor UDP-MurNAc, which is further converted to
UDP-MurNAc-pentapeptide by ATP-dependent amino acid ligases. The
disaccharide unit is attached to a carrier lipid C55 polyprenol (C55-P) in
the cytoplasmic membrane leading to the formation of lipid I by MraY and
further to lipid II by the glycosyltransferase MurG. The lipid-linked disac-
charide lipid II is flipped across the cytoplasmic membrane by MurJ and
other flippases. At the periplasmic site of the membrane, lipid II is poly-
merised and new glycan units are inserted into the cell wall, involving gly-
cosyltransferases and transpeptidases (penicillin-binding proteins) [12,14].
1.4 Biological membranes and membrane pro-
teins
Life is highly complex and full of wonders. From the tiniest bacterial species
to huge mammalian animals, they all would be incapable of thriving and
functioning without biological membranes. These composite structures en-
able the formation of cells, the basic units of a living organism. A biological
membrane is the outer cover layer that separates the cell from its environ-
ment - this layer is not rigid but instead fluid and allows movement within
the membrane [18]. Due to the composition of a biological membrane,
its selective permeability discriminates which substances to exchange with
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Figure 1.2: Peptidoglycan synthesis. Simplified schematic of the peptidoglycan
synthesis illustrating the involved proteins. The illustration is inspired from [17]
.
the environment. The creation of ion gradients across membranes gener-
ates energy, and membranes regulate the communication between differ-
ent cells by receiving or sending information in the form of chemical or
electrical signals.
Biological membranes are composed of lipid molecules that form the
typical phospholipid bilayer. Next to different types of lipids, membrane
proteins and sugars are part of biological membranes. Given the amphi-
pathic composition of lipids, the molecules naturally form a bilayer so
that the hydrophilic head groups face towards aqueous solution and the
hydrophobic tail groups are pointing inwards facing each other. Membrane
lipids will spontaneously form so-called liposomes, which are spheres made
of a lipid bilayer, when exposed to aqueous solution. This conformation
represents the most favourable state of the lipid molecules thermodynam-
ically [19].
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Membrane proteins are vital for the structural integrity of membranes
and are the macromolecular machines responsible for cell signalling and
the transport of substances through the membranes. Depending on what
type of membrane proteins are present in a membrane, different types
of signalling molecules can be recognized, and certain chemicals will be
permeable through the membrane. Membrane proteins are complex macro-
molecules with unique biophysical characteristics that determine their
structure. Due to their natural occurrence in a lipid bilayer, their bio-
physical composition differs from soluble proteins, which are exposed to
an aqueous solution. Membrane proteins are both in contact with the
lipid bilayer as well as the aqueous solution of the respective intracellular
or extracellular compartment. However, they are synthesised in the same
way as soluble proteins - by ribosomes - and will then be relocated to
the designated location of a membrane. This aspect requires challeng-
ing or even conflicting demands on the folding and stability of membrane
proteins [20].
Knowledge of the structure of membrane proteins can give crucial
information about their respective biological function. Many membrane
proteins are potential drug targets involved in cell signalling or growth
control, which makes them particularly interesting for the pharmaceu-
tical industry [21]. Membrane proteins classify as integral or peripheral
membrane proteins. The latter is not embedded into the membrane but
instead associated with it, either directly to the phospholipids or indi-
rectly via integral membrane proteins. Integral membrane proteins consist
of membrane-spanning domains, which are commonly composed of α-
helices or β-barrels. β-barrel membrane proteins usually form pores, with
hydrophobic side chains pointing towards the lipid bilayer and the ma-
jority of all known β-barrel membrane proteins show hydrophobic amino
acids at every second residue in the primary sequence that direct to the
interior of the lipid bilayer. This type is near without exception found in
the outer membranes of bacterial cells, mitochondria or chloroplasts. In
contrast, the α-helical membrane proteins are mostly found in cytoplasmic
or subcellular membranes.
9
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In the case of α-helical membrane proteins, there is at least one hy-
drophobic transmembrane-spanning α-helix, which is composed of ap-
proximately 20 amino acids. This transmembrane stretch is around 30 Å
long corresponding to the thickness of a phospholipid bilayer. Hydrophobic
interactions with the interior of the lipid bilayer stabilise the transmem-
brane α-helical domains, and hydrophobic side chains of the polypeptide
chain shield the polar peptide bonds and form van der Waals interactions
with the fatty acid chains. Besides, the carbonyl and imino groups of
the peptide bonds form hydrogen-bonds to each other, thus revealing the
characteristic helix shape [20].
Important classes of membrane proteins comprise:
• Channels
• Pores
• Transporters
• G-protein-coupled receptors (GPCRs)
• and membrane enzymes.
1.5 MraY and the PNPT superfamily
The PNPT superfamily is a large group of integral membrane enzymes.
Their family members are prokaryotic and eukaryotic sugar prenyltrans-
ferases, which catalyse the transfer of phospho-N-acetylhexosamine from
a UDP-N-acetylhexosamine sugar nucleotide donor substrate - located
in the cytoplasm - to a membrane-bound polyprenyl phosphate acceptor
substrate [22]. The prokaryotic family members include the MraY, WecA,
TagO, WbcO, WbpL and RgpG enzyme families and are involved in the
peptidoglycan synthesis of bacterial cell walls [23]. Despite sharing a com-
mon lipid substrate, undecaprenyl-phosphate (C55-P), their distinct UDP-
sugar donor substrate distinguishes the family members [24]. The PNPT
family contains only one eukaryotic member, UDP-N-acetylglucosamine:
dolichyl phosphate N-acetyl-glucosamine-1-phosphate transferase or GlcNAc-
1-P-transferase (GPT) crucial for protein N-linked glycosylation and present
10
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in the membrane of the endoplasmic reticulum. GPT uses UDP-GlcNAc
as donor substrate and the membrane-bound dolichol phosphate as an
acceptor substrate [25].
The PNPT family member MraY (UDP-N-acetylmuramyl-pentapeptide:
undecaprenyl phosphate N-acetylmuramyl-pentapeptide-1-phosphate trans-
ferase or MurNAc-1-P-transferase) is a transmembrane enzyme involved
in the first membrane-bound step of the peptidoglycan synthesis. Given
that MraY is vital for bacterial survival, it is a promising drug target for
the development of novel antibiotics, and MraY is only present within the
bacterial family members and does not exist in eukaryotes [26].
MraY catalyses the synthesis of the peptidoglycan precursor lipid I
(C55-PP-MurNAc-pentapeptide) by using UDP-MurNAc-pentapeptide as
the donor substrate and C55-P as the lipid acceptor substrate, resulting
in uridine monophosphate (UMP) as a side product, which acts as a weak
MraY inhibitor [27,28]. Figure 1.2 illustrates the MraY reaction. A debate
was ongoing whether the MraY reaction acts via a one-step or a two-step
mechanism [29] and it was concluded from a detailed catalytic study [30]
that the reactions occurs via a single displacement mechanism, where both
the UDP-sugar substrate and the lipid substrate are bound simultaneously
in the active site (Paper II).
Studies on different MraY homologues led to expressed and at least
partially purified protein [31–33]. Nevertheless, not until 2013, Lee and
coworkers [34] solved the first crystal structure of MraY, from the ther-
mophilic Aquifex aeolicus (AaMraY), being the first structure of a PNPT
superfamily member. Since then, several structures of MraY in complex
with inhibitors - including our structure of Clostridium bolteae in complex
with tunicamycin [35] - have been solved, followed by the recent structures
of human GPT. All available structures of the PNPT family members are
listed in Table 1.
11
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Structures of the PNPT family members
Protein/Ligand PDB ID Resolution
(Å)
AaMraY/apo [34] 4J72 3.3
AaMraY/MD2 [36] 5CKR 2.96
CbMraY/tunicamycin [35] 5JNQ 2.6
AaMraY/3´-hydroxymureidomcin A [37] 6OZ6 3.7
AaMraY/carbacaprazamycin [37] 6OYH 2.95
AaMraY/capuramycin [37] 6OYZ 3.62
humanGPT/apo [38] 5LEV 3.2
humanGPT/apo [38] 6FM9 3.6
humanGPT/tunicamycin [38] 5O5E 3.4
humanGPT/tunicamycin [39] 6BW5 3.1
humanGPT/tunicamycin [39] 6BW6 2.95
humanGPT/UDP-GlcNAc [38] 6FWZ 3.1
Table 1.1: Crystal structures of the PNPT superfamily members divided into
bacterial MraYs and human GPT.
1.6 Tunicamycin
Tunicamycin belongs to a class of natural product inhibitors targeting
MraY, including the liposidomycins/caprazamycins, capuramycins, murei-
domycins, muraymycins, and tunicamycins. Figure 1.3 illustrates the groups
of nucleoside inhibitors with a representative of each group. The uridine-
derived nucleoside antibiotic consists of a uridine conjugated to an 11-
carbon amino-deoxy dialdose (tunicamine), an N-acetylglucosamine sugar
(GlcNAc) as well as a fatty acid tail of varying length (13-17 carbons),
branching type and saturation. Tunicamycin acquired its name due to its
antiviral activity by inhibition of a viral coat, also named "tunica" [12].
Tunicamycin was first identified in Streptomyces lysosuperificus in 1973.
Due to its ability to block GPT, tunicamycin is a common tool com-
pound to study N-linked glycosylation and has been used extensively
12
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Figure 1.3: The classes of nucleoside inhibitors of MraY. Illustration of the
classes of MraY nucleoside inhibitors and their representatives (A) tunicamycin,
(B) muraymicin D2, (C) capuramycin and (D) mureidomycin.
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since its discovery for studying the role of N-glycans in glycoprotein func-
tions [40] [41]. Furthermore, tunicamycin is preferentially inducing apop-
tosis in cancer cells and is, therefore, a promising compound for use in
cancer treatment. Next to its ability to blocking N-linked glycosylation,
tunicamycin is an effective MraY inhibitor and thereby able to block cell
wall synthesis in bacteria. It is instrumental in inhibiting the peptidoglycan
synthesis in Gram-positive bacteria but in contrast, shows no activity in
Gram-negative bacteria due to its inability to permeate through the outer
membrane [42]. Given its effectiveness in inhibiting N-linked glycosylation,
leading to protein misfolding and cell cycle arrest, tunicamycin is toxic to
human cells and therefore not in use as an antibiotic.
Tunicamycin is a potent competitive inhibitor as it resembles the donor
nucleotide sugar substrate in the MraY and GPT reactions; it shows IC50
values in the range 10 nM to 2000 nM for MraY [42–45] and 9 nM to
200 nM for GPT [39, 46, 47]. Even though tunicamycin shows cytotoxic
effects, modified tunicamycins have shown reduced eukaryotic toxicity:
reduction of the trans-2,3 double bond in the N-acyl chain leads to the
compound TunR1, and additional reduction of uracil ring - resulting in
5,6-dihydrouracil - leads to compound TunR2 with a significantly reduced
toxicity against eukaryotic cell lines [48,49]. Further modification of TunR2
via hydrolytic ring opening reveals TunR3 that shows reduced potency in
both bacteria and yeast [48] - which is in agreement with studies on a
similar compound in mammalian cells by Hashim and Cushley [50]
Other types of tunicamycin homologues occur besides the classic tu-
nicamycin from S. lysosuperificus [41] and S. chartreusis [51], includ-
ing corynetoxins [52]- the N-acyl chain is hydrolated -, streptovirudins -
the uridine group is replaced by dihydrouracil-, and the quinovosamycins
(QVM) - the GlcNAc motif is replaced with QuiNAc [53].
1.7 Structure-based drug design
SStructure-based drug design (SBDD) is the rational design and optimi-
sation of a compound with the potential of becoming a drug candidate
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in clinical trials. The history of SBDD begins in the mid-’80s, and the
first breakthrough lead to HIV protease inhibitors in the mid-’90s [54,55].
SBDD is nowadays an integrated part of drug discovery that together with
recent advances such as the completion of the Human Genome Project,
advances in bioinformatics leading to identification of a vast number of
protein targets, and significant progress in molecular and structural biol-
ogy, has resulted in more than 100.000 protein structures [56,57].
The process starts with the selection of the target, followed by cloning,
gene expression and purification. High throughput screening (HTS) is
still the most common way to find starting molecules (hits) where up
to 1,000,000 compounds are screened in each project, but other methods
can also be used such as fragment screening and virtual library screening.
In the next step the molecules are confirmed to bind in an orthogonal assay
and structure based drug design is started, that is iterative crystallogra-
phy support to guide the design of new optimised molecules by visualising
the ligand binding in the protein ligand complex. The new compounds are
tested for activity and new structures are generated, building an under-
standing of the structure activity relationship (SAR), improving the affinity
and activity. The SBDD involves many design cycles, many structures of
the same target but with new compounds are delivered and structural
information and guidance how to optimise the molecule is fed into the
project. SBDD is of importance also in the lead optimisation phase where
the leads have been identified and will be optimised until a candidate drug
has been delivered into the development phase where the drugs are devel-
oped into medicines. Then the clinical trials are started; Phase 1 (healthy
volunteers to test toxicity), Phase 2 (a small population with disease to
test efficacy), Phase 3 (final testing at a larger population with disease)
and Phase 4 (post approval studies).
1.8 Scope of this thesis
This thesis summarises the work involved with the bacterial membrane
protein MraY - including structural and biophysical studies with inhibitors
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for the future development of antibacterial agents, and methods to opti-
mise membrane protein purification.
Chapter 2 provides a brief introduction to the methods that I have used
throughout this thesis.
Chapter 3 summarises and discusses the results from
Paper I - Paper IV.
Chapter 4 is concluding the results and presents future perspectives.
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Methodology
2.1 Expression and purification
The study of membrane proteins is of utmost importance due to their
biological and pharmacological significance, even though the experimen-
tal procedure is particularly challenging amongst protein biochemists. In
order to study the functional and structural characteristics of a mem-
brane protein, the protein has to be extracted from its natural amphiphilic
environment and isolated in an active and stable form [58].
The experimental work starts with the overexpression of the protein in
a selected host organism; the easiest and cheapest option is the use of
bacterial strains as hosts. Escherichia coli (E. coli) is the most common
system for recombinant expression of proteins. In more complicated cases
- such as for eukaryotic membrane proteins - the use of eukaryotic cells as
expression system may be required due to the lack of specific chaperones
and post-translational modifications in prokaryotic systems.
The selected host cells will produce the protein of interest in large
amounts. In order to get access to the protein, the cells will be collected
by centrifugation and chemically / physically broken (lysed). A centrifu-
gation step will remove the cell debris, and the cell membranes containing
the membrane protein of interest are isolated by ultracentrifugation. In the
next step, the membrane proteins will be extracted from the membrane
by the use of detergents. The resulting membrane protein-detergent mi-
celles are purified by chromatographic methods, and SDS-PAGE (sodium
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dodecyl sulfate polyacrylamide gel electrophoresis) and UV-VIS (ultravio-
let–visible spectrophotometry) will verify the purity.
Immobilised metal affinity chromatography. Immobilised metal affin-
ity chromatography (IMAC) is a specific type of affinity chromatography,
which was first introduced by Porath and coworkers [59] in 1989 and is
the most common protein purification method. During IMAC, the proteins
are separated due to their specific affinity for certain metal ions, which
form chelating complexes with an insoluble matrix, comprised of resin or
beads that can be packed to a column [60]. The amino acids histidine,
tryptophan and cysteine form complexes with the immobilised metal ions
around neutral pH.
In recombinant protein purification, IMAC is commonly used in com-
bination with a poly-histidine fusion, which is tagged to the protein of
interest. The poly-histidine tag is a chain of histidine residues located at
either the N-terminus or C-terminus of the recombinant protein and has a
high affinity for metal ions, which are immobilised to the IMAC matrix. The
most commonly used metal ions are Ni2+, Co2+, Cu2+ and Zn2+ [61].
Other proteins will only bind weakly to the matrix, which are removed
during washing steps. Imidazole is a five-membered aromatic molecule
containing two nitrogen atoms and is part of the side chain of the amino
acid histidine. Therefore, imidazole is competing with the poly-histidine
tag for chelating of the metal charged IMAC resin, and thus elutes the
recombinant protein. Due to the high affinity of the method, a protein
sample of up to 95% purity may be achieved after this single purification
step.
Size exclusion chromatography. Size exclusion chromatography (SEC)
- or gel filtration chromatography - is usually added as a polishing step
after IMAC in order to further purify and optimise the sample quality
and homogeneity. During SEC, the proteins and molecules present in the
sample will separate according to their size (molecular weight) as they
pass through a SEC matrix packed in a column. It is considered as one
of the mildest chromatography methods as the molecules do not bind to
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the matrix. The SEC matrix or resin consists of porous, spherical parti-
cles without adhesive or reactive properties. Once the sample enters the
SEC column, molecules that are larger than the pores will elute first. The
smaller molecules will penetrate the pores in different ways according to
their size, and the ones that can penetrate the pores completely will elute
last [62].
Solubilisation of membrane proteins. The probably most critical step
during membrane protein purification is the solubilisation of the membrane
in order to extract the membrane protein. The aim is to maximally perturb
the lipid composition of the membrane and bringing the membrane pro-
teins in an unnatural environment in detergent micelles while maintaining
an active and stable conformation - necessary for further experiments [63].
Detergents. Detergents are amphipathic molecules composed of a hy-
drophilic head group, which is polar or charged, and a hydrophobic carbon
tail. Detergents are classified based on their chemical composition as ionic,
zwitterionic or non-ionic detergents. Due to their amphipathic structure,
the polar head groups form hydrogen bonds with water in aqueous so-
lution, and the hydrophobic tails will aggregate and form hydrophobic
interactions. As a result of their unique properties, detergents find appli-
cations in the solubilisation of membrane proteins, cell lysis and protein
crystallization [64].
In aqueous solution, detergents are present as monomers at low con-
centrations. Detergent monomers will spontaneously start forming non-
covalent micelles above a specific concentration - the critical micelle con-
centration (CMC). The CMC varies for different detergents and is depend-
ing on different factors such as pH, ionic strength and temperature [64].
At concentrations above the CMC, the detergent micelles can form com-
plexes with membrane proteins; thus, the CMC is an essential parameter
in membrane protein biochemistry. Detergent micelles represent an amphi-
pathic environment that is similar to phospholipid bilayers, which makes
the use of detergents as solubilizing agents so crucial in functional and
structural studies of membrane proteins.
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At low concentrations, the detergent monomers perturb the phospho-
lipid membrane by partitioning into the bilayer without solubilising the
membrane proteins. At concentrations equal to or above the CMC, the
membrane bilayer will rupture as it gets saturated with detergent molecules
- resulting in lipid-protein-detergent mixed micelles. This event typically
occurs at a detergent/protein ratio of 1/2 (w/w) [65]. A further increase
in detergent concentration will cause delipidation of the mixed micelles
leading to detergent-protein mixed micelles and detergent-lipid mixed mi-
celles. Figure 2.1 sketches the principle of the solubilisation process.
2.1.1 Expression of CbMraY
In this work, Clostridium bolteae MraY was recombinantly overexpressed
in E. coli cells. A detailed description of the method is found in Pa-
per III. The CbMraY construct included an N-terminal PelB signal se-
quence, a TEV cleavable N-terminal split GFP sequence and a C-terminal
His10 tag in the pET26b+ plasmid [32, 35]. CbMraY protein was over-
expressed in E. coli BL21(DE3)Gold cells in Super Broth medium as
500-ml cultures containing kanamycin and D-(+)-Glucose in flasks. Cells
were grown to OD600 = 0.7–0.9 at 37 °C and 210 r.p.m (rounds per
minute). Protein expression was induced with IPTG at 18°C for 17–18
hours. Harvested cells were resuspended in HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) buffer and either flash-frozen in liquid
nitrogen and stored at -80°C or subsequently used for purification.
2.1.2 Preparation of membranes containing overexpressed
CbMraY for inhibition measurements.
Membranes containing overexpressed CbMraY wild-type or mutant pro-
tein were prepared for the use in inhibition measurements described in
section 3. CbMraY proteins were overproduced in E. coli BL21(DE3)Gold
cells in SB medium as 100-ml cultures and further steps were performed
as stated above in section 2.1.1. Freshly harvested or frozen cells were
taken in lysis buffer, and cells were lysed in a constant system cell dis-
rupter. The cell debris was removed by centrifugation and membranes
were isolated by ultracentrifugation at 138,000 × g and resuspended in
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Figure 2.1: The process of solubilisation Simplified scheme of the solubilisation
of membrane proteins.
membrane buffer. Equal expression levels of MraY proteins was verified
by FSEC (Fluorescence-Detection Size-Exclusion Chromatography). To-
tal membrane protein concentration was determined via Bradford assay
(BioRad kit) using a BSA (Bovine Serum Albumin) standard curve.
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2.1.3 Purification of CbMraY
All steps were carried out at 4°C. Cells were lysed in a constant system cell
disruptor, and protein was extracted from the crude lysate by addition of
dodecyl-maltoside (DDM). Insoluble fractions were removed by centrifu-
gation, and the supernatant was incubated with cobalt Talon resin in batch
mode overnight and washed with IMAC buffer the following morning. Fol-
lowing IMAC, the detergent was exchanged to decylmaltoside (DM), and
protein was eluted in elution buffer containing imidazole. The protein was
subsequently concentrated using spin concentrators with 50 kDa cutoff,
and size-exclusion chromatography was carried out using a Superdex 200
10/30 column (GE Healthcare) in combination with Äkta system. The
protein was stored at 4°C for subsequent experiments or flash-frozen in
liquid nitrogen and stored at -80°C.
2.2 Functional studies of CbMraY and ligand
interactions
The following section will give a brief overview about the different methods
that were used to study the functional characteristics of CbMraY and its
interactions with different inhibitors. The methods are described in detail
in Paper I and Paper III.
2.2.1 Enzymatic activity assay
The assay used to measure the enzymatic activity of CbMraY is based
on Fluorescence resonance energy transfer (FRET). FRET is a physi-
cal process, which involves non-radiative energy transfer from an excited
donor fluorophore molecule to an acceptor fluorophore due to intermolec-
ular long-range dipole-dipole coupling [66]. FRET is a highly sensitive,
distance-dependent method to investigate molecular proximities in Å-
range (10-100 Å). The so-called Förster radius gives the distance at which
half of the excitation energy is transferred from the donor to the accep-
tor fluorophore molecule and typically lies between 3-6 nm [67]. FRET
is most efficient if donor and acceptor are oriented within the Förster
radius [68,69].
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FRET-based assay to detect MraY enzyme activity The FRET-
based assay used to measure MraY enzymatic activity was initially devel-
oped by Shapiro and coworkers [44] in a high-throughput set up to screen
for MraY inhibitors. The original protocol was designed for measuring
MraY activity in membranes. In this work, the protocol was adopted -
suitable for small-scale use.
Figure 2.2: Illustration of the FRET-based activity assay. Detergent micelles
(grey head groups) contain MraY protein (cyan), undecaprenyl phosphate (C55-
P, blue head-groups) and the FRET acceptor LRPE (pink). UDP-MurNAc-
pentapeptide is labelled with the FRET donor (BODIPY-FL) and comes in
close proximity to the FRET acceptor upon MraY reaction. The illustration is
inspired from [17].
In the FRET assay, the donor fluorophore BODIPY-FL with an emission
wavelength of 520 nm is attached to the soluble substrate of MraY, UDP-
MurNAc-pentapeptide. 1,2-dipalmitoyl-sn-glycero-3-phos-phoethano-lamine-
N-(lissamine rhodamine B sulfonyl (LRPE)) acts as acceptor fluorophore
with an emission wavelength of 590 nm, which is incorporated in the
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lipid-detergent-protein mixed micelles or detergent-protein mixed micelles.
During the MraY translocase reaction, UDP-MurNAc-pentapeptide will
be attached to C55-P, therefore bringing donor and acceptor fluorophore
in proximity sufficient for FRET as illustrated in Figure 2.2. Excitation
at 480 nm will initiate FRET, hence reducing the donor fluorescence at
520 nm and increasing the acceptor fluorescence at 590 nm. MraY enzy-
matic activity is visualised as progress curves by plotting the ratio of F590
nm/F520 nm against the reaction time [44].
In Paper I, initial rates were calculated from the change in the 520nm
fluorescence signal (∆F520), which follows the uptake of UDP-MurNAc-
pentapeptide for the first two minutes of the reactions using a linear fit.
Therefore, the assay was performed in the presence (5mM) and absence
(0mM) of UMP, which acts as MraY inhibitor, in order to subtract the
baseline. The resulting process curves reflect the MraY enzymatic activity.
2.2.2 Inhibition measurements
The FRET-based activity assay was used in order to investigate the po-
tential inhibition of CbMraY by different compounds. The assay was per-
formed in black well plates in a PheraStar plate reader. E. coli membranes
containing overexpressed CbMraY were pre-incubated with different con-
centrations of compounds, C55-P and LRPE in assay buffer before initiat-
ing the reaction with UDP-MurNAc-pentapeptide. The compounds were
diluted in assay buffer from stock solutions in DMSO. Fluorescence was
excited at 485 nm and detected simultaneously at 520nm and 590nm,
every minute for 35 minutes. Control experiment to verify MraY activ-
ity were performed without compounds and 2% DMSO representing the
highest DMSO concentration that was used in the assay. Average progress
curves with membranes in the absence of overexpressed CbMraY were
subtracted from the average progress curves with membranes containin-
ing overexpressed CbMraY to obtain ∆(F590/F520). The first measuring
point of the reaction (starting point at 0 minutes) was subtracted from
the last (endpoint at 35 minutes) to calculate the response. IC50 values
were then calculated using a nonlinear regression curve fit with a variable
slope (four parameters) in GraphPad Prism version 8.0.0.
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2.2.3 Isothermal Titration Calorimetry
Isothermal Titration Calorimetry (ITC) is the measurement of binding
affinity and thermodynamic parameters of biomolecular interactions. The
method is based on the direct measurement of heat that is either released
or absorbed during a binding event under constant temperature. It is a
compelling label-free technique that does not require immobilization of
the binding partners and thus measures the binding event in solution [70].
During an ITC experiment, one will determine the binding constant KD,
the reaction stoichiometry (n), enthalpy (∆H) and entropy (∆S). Careful
examination and interpretation of the determined thermodynamic parame-
ters can give a deep insight into molecular mechanisms behind the binding
event such as conformational changes [71].
During an ITC experiment, a ligand is gradually titrated from a syringe
into a sample cell containing a potential binding partner. In the event
of binding, the absorption or release of heat is detected by a sensitive
calorimeter. A reference cell containing water is required in order to detect
the heat change in case of binding. The sample cell is then readjusted to
equal temperature as the reference cell. The instrument will maintain the
temperature of the sample cell by adjusting the power accordingly to the
binding event. Integration of the power over time will give the heat change,
which is the enthalpy of the reaction [71].
Even though ITC is a powerful technique, its sensitivity requires the
thorough design of the experiment and sample preparation. The buffers
of the protein sample and the ligand have to be matching as even small
discrepancies can affect the experiment in such a way that the readout
can not be interpreted correctly.
A critical parameter that will affect the outcome of the ITC experiment
is the c value, which determines the binding isotherm of the experiment.
The c value is defined as c = nPtKd where Pt is the protein concentration,
n is the number of binding sites per protein molecule, and KD is the
binding affinity constant. The c-value will affect the shape of the binding
curve, which should preferably have a sigmoidal shape and should not be
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too steep or too shallow. Therefore, by adjusting the protein and ligand
concentration can give a desired c value in the range of 5-1000 [72].
In this work, CbMraY wild-type protein was purified as described in
section 2.1.3. The ligands were diluted from stock solutions in DMSO
in a SEC buffer that was matching the final protein buffer. Appropriate
amounts of DMSO was added to the protein sample to match the DMSO
concentration of the ligand samples. All experiments were run in tripli-
cates at 25°C. In order to verify that the buffers of protein and ligand
samples were matching, control experiments were performed in advance.
The controls were involving the titration of sample buffer into the protein
sample and the titration of the ligand into the sample buffer. The control
can give information about the background heat, which is generated by
the biological system and can be subtracted from the actual experiment.
2.2.4 Water-LOGSY NMR
Water-LOGSY (Water-Ligand Observed via Gradient SpectroscopY) is a
sensitive NMR experiment to observe and characterise the binding of a
ligand to a macromolecule of interest [73]. The binding experiment is a
variant of STD (Saturation Transfer Difference), meaning the source mag-
netisation is derived from bulk water protons. In this type of experiment,
the ligand binding is indirectly observed via NOE (Nuclear Overhauser
Effect) [74].
Inhibition of CbMraY by tunicamycin was indirectly observed by the
implementation of a competitive ligand binding assay [75] as the signal
derived from tunicamycin was not believed to be sufficient. Therefore,
purified CbMraY was added to UMP, which acts as a weak inhibitor of
MraY. In the next step, tunicamycin is titrated into the sample in order
to examine if tunicamycin has the ability to compete out UMP and bind
to MraY. In this case, the observed binding derives from UMP.
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2.2.5 Thermal stability of MraY
Knowledge about the thermostability of proteins can give valuable in-
formation about the physical and chemical processes involved in protein
folding. The thermal stability of a protein is usually determined by the
thermal unfolding transition midpoint Tm (°C), which is defined as the
temperature at which half the protein population is unfolded [76]. During
a thermostability experiment, the unfolding process of a protein due to
heat is monitored. Addition of chemical additives such as drug compounds
can affect the kinetics of protein denaturation and result in a shift of the
protein denaturation curve, which represents the heat-induced unfolding
process of a protein over time [77]. Thermostability assays are useful tools
to characterise membrane protein stability, to compare the quality of dif-
ferent protein samples and to screen for buffers and detergents.
The thermal stability of CbMraY and the effect of selected inhibitors on
the heat-induced unfolding was observed with label-free nano DSF, which
is a differential scanning fluorimetry technology. The thermal stability is
derived by monitoring changes in tryptophan fluorescence present in the
protein of interest. As the intrinsic tryptophan fluorescence is depending on
the protein structure, thermal unfolding will lead to shifts of fluorescence
emission peaks and changes in fluorescence intensity. Thermal unfolding
curves are obtained, and Tm of the protein can be calculated from changes
in tryptophan fluorescence intensity or the ratio of tryptophan emission at
350nm and 330 nm corresponding from the shift of tryptophan emission
due to unfolding of the protein.
For this thesis, purified CbMraY wild-type protein was prepared as de-
scribed in section 2.1.3. Nano DSF experiments were performed for the
apoprotein and in the presence of different inhibitors diluted in protein
buffer from stock solutions in DMSO. A control experiment was includ-
ing apoprotein in the presence of DMSO. Melting curves were obtained
via a heat gradient from 25°C - 95°C at 1°C/min using a Prometheus
(NanoTemper).
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2.3 Protein-ligand docking
Docking experiments have become a powerful tool in structure-based drug
discovery. The ability to dock an extensive library of compounds into
the active site of a target protein enables a more efficient and less cost-
intensive approach in finding potential hits, as fewer compounds need to
be tested experimentally. Besides virtual screening of compounds, dock-
ing can be used for the prediction of protein-ligand interactions, providing
useful information about the active site geometry of a protein-ligand com-
plex [78].
In order to study the ligand interactions of tunicamycin with GPT,
the compound has been docked into the active site of apo human GPT
(PDB ID: 5LEV). The protein-ligand docking experiment has been per-
formed using the Glide docking and scoring methodology provided by the
Schrödinger Maestro software package. The method is based on the "In-
duced Fit" docking protocol. The scoring functions in Glide rank the ligand
poses according to their calculated binding affinity (kcal/mol) [79, 80].
Before the docking experiment can be started, the protein file needs
to prepared in Schrödinger, including adding and optimisation of hydro-
gens, removal of water molecules and assignment of the active site via
generation of a grid. In the next step, a 3D structure of the ligand will
be generated. Hydrogens are added, and protonation and tautomer states
are assigned. Finally, the docking experiment can be initiated.
2.4 Protein Crystallisation
To determine the 3D structure of proteins is of utmost interest for medical
applications and the pharmaceutical industry. X-ray crystallography has
long been - and still is in most cases - the standard technique in structural
biology of proteins. Even though the technique is relatively mature, it relies
on the production of pure and homogenous samples to produce high-
quality crystals, which remains a major bottleneck in structural biology
[81].
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In order to initiate protein crystallisation, it is necessary to reach a
supersaturated state of the solution that contains the proteins and at
the same time, do not disrupt their native states [82]. Supersaturation is
achieved by adding mild precipitating agents - such as salt and polymers -
and by adjusting the temperature, pH and ionic strength. Despite protein
crystallography being an old technique, the experiments are still to a large
extent relying on a combination of trial and error and experience, and we
are only now starting to explore the physical processes that initiate crystal
formation and phase transition [83,84].
Membrane protein crystallisation The importance of membrane pro-
teins and their challenges in structural biology was mentioned in section
1.4. Due to their hydrophobic nature, membrane proteins are notoriously
difficult to work with, and as a consequence, they are underrepresented in
the structural protein database PDB [85].
The process of membrane protein crystallisation starts with a large
screen of crystallisation reagents that might initiate crystal formation.
Advances in the field over the last decade enable automated crystallisa-
tion screening using robotics, and commercial kits are available that es-
pecially favour crystallisation of membrane proteins [86, 87]. In the event
of initial crystal hits, the conditions require further optimisation to obtain
well-diffracting crystals.
The use of a lipidic cubic phase (LCP) may be advantageous for the
crystallisation of membrane proteins: here the membrane proteins are re-
constituted - out of the detergent micelle - into a lipidic cubic phase
that enables free diffusion of the proteins in the continuous lipidic cubic
phase [88]. LCP mimics the natural environment of membrane proteins as
it forms bilayers composed of neutral and native lipids [89].
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Structure-based drug
discovery applied to
CbMraY
The following section summarises the work performed with the bacterial
membrane protein CbMraY, beginning with our complex structure and
ending with the biophysical characterisation of modified tunicamycins to-
gether with a rationalisation of selective MraY inhibitors.
3.1 The crystal structure of CbMraY
We have solved the crystal structure of CbMraY in complex with the
natural product inhibitor tunicamycin [35] as part of this project in 2017
(Paper I). A detailed description of the active site with the bound in-
hibitor is provided in section 3.1.1 and (Paper I and Paper II); CbMraY
numbering is used throughout in section 3 unless stated otherwise. The
overall structure of CbMraY is similar to AaMraY; it comprises ten trans-
membrane helices (TM1-TM10) with both the N terminus and C terminus
located on the periplasm, five cytoplasmic loops (loops A, B, C, D and E)
and four extracellular loops (Figure 3.1). The periplasmic β-hairpin and
the additional periplasmic helix between TM6 and TM7 are incomplete
in our structure (in contrast to AaMraY). The glycine residue G258 -
conserved throughout the bacterial MraYs - breaks TM9 into two helical
segments (TM9a and TM9b), creating a 50° bend at the second half of
TM9 relative to the membrane [34–36]. Thus TM9b protrudes 20 Å into
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the lipid bilayer. In contrast to the apo AaMraY, CbMraY contains helix
9c (also called the loop-E-helix) consisting of 11 residues located between
TM9 and TM10, which is consistent in all available complex structures of
MraY.
Figure 3.1: Crystal structure of CbMraY. (A) Overall structure of CbMraY
(PDB ID: 5JNQ) in complex with tunicamycin (orange). Dotted lines indicate
the orientation in the lipid membrane. The figure is based on [90]. (B) Active
site view in surface representation with bound tunicamycin. Residues of the
catalytic triad and the HHH motif are represented as sticks.
The active site of CbMraY is composed of a cytoplasmic cleft contain-
ing several conserved polar and charged amino acid residues (discussed
in section 3.1.1). Helix 9c forms one side of the cytoplasmic cleft, which
is lined by TM5-TM10 and loops C and D and contains catalytically es-
sential amino acid residues including the aspartic acid triad and the HHH
motif [24]. The catalytically active Mg2+ ion is absent in the CbMraY
structure; in contrast to the apo AaMraY structure, where the Mg2+
ion is interacting with D231 (D265 AaMraY). The absence of magne-
sium in the CbMraY structure is due to the direct interaction of D231
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with tunicamycin - it has been shown that tunicamycin is competing with
magnesium [36, 37]. Thus even in the presence of Mg2+ MraY would be
incapable of binding tunicamycin and Mg2+ simultaneously [35].
Ligand binding seems to induce significant conformational changes in
MraY as shown by the MraY complex structures, which is in stark contrast
to the apo AaMraY structure that is lacking a well defined active site. Also,
a recently published structure of AaMraY in complex with capuramycin
shows that Loop E is disorder - similar to the apo structure - as the com-
pound is not occupying this part of the active site (Mashalidis, 2019);
but, different to the apo structure, helix 9c is well defined. In contrast,
the apo GPT structures (PDB ID: 5LEV and 6FM9) reveal a well defined
active site, which is very similar to the ligand-bound structures (Paper
II, Section 3.3). The difference between the apo MraY and the complex
structures may reveal major conformational changes due to ligand binding
or may be a result of crystal packing. Despite missing an apo CbMraY
structure, thermal stability measurements with CbMraY seem to indicate
bigger structural changes upon tunicamycin binding as well: Figure 3.2 il-
lustrates nano DSF measurements comparing apo and tunicamycin bound
CbMraY (unpublished data collected as part of this project). Analysis of
the ratio F350nm/330nm reveals, in addition to the thermal shift, a dis-
tinct pattern of the melting curves, which distinguishes ligand-bound from
the apo structure. It would be interesting to investigate the respective
melting curves of apo and tunicamycin bound GPT [38]. These melting
curves are expected to show high a similarity between apo and ligand-
bound GPT - regardless of the significant thermal shift (∼ 30◦C [38]).
CbMraY, as seen in all available MraY structures, crystallises as a dimer.
The dimerisation interface in CbMraY is comprised of TM1, TM7 and
TM10 forming a central hydrophic tunnel with a detergent molecule and
a lipid tail bound in our structure (Paper I, Paper II). The interface lipids
are suggested to play a role in regulation of the enzymatic activity [39,91].
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Figure 3.2: Thermal stability of CbMraY. Normalised melting curves of apo
CbMraY (red), in complex with tunicamycin (black) and in complex with UMP
(cyan).
3.1.1 Active site geometry
Our CbMraY-tunicamycin complex reveals a detailed active site pocket
with the bound natural product inhibitor as presented in Paper I and
Paper II (Figure 3.3 provides a ligand interaction map). As described in
the previous section, tunicamycin is bound in a wide cytoplasmic cavity,
forming interactions with residues F173, G176, N221, F228, N172, D175,
D178, D231, H290, H291. The cavity formed by residues G176, N221 and
F228 wedges the uracil ring of tunicamycin and N221A and F228A mu-
tants lead to almost complete inactivation of CbMraY. The uracil ring is
coordinated by N221, D178 and by L177 via backbone interactions, while
the uracil base stacks against F228 via pi-pi interactions. The HHH motif
is part of the amphiphilic helix 9c in CbMraY consisting of the residues
H290, H291 and H292 - these residues form major interactions with tuni-
camycin and are conserved among the MraYs [24,92]. The GlcNAc ring of
tunicamycin interacts with H291 and stacks against F173 and P288. Our
mutations of residue H290 led to almost complete enzyme inactivation.
Residue D175 interacts with the 5´-hydroxyl group of tunicamycin, con-
firmed by our mutational studies showing that D175 is crucial for MraY
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activity. The position of the fatty acyl tail of tunicamycin is absent in the
CbMraY structure due to poor electron density. However, the interaction
of the fatty acid amide in tunicamycin with the residue N173 suggests the
fatty acyl tail stretches along TM5 into the membrane, which is further
supported by the GPT-tunicamycin structure discussed in section 3.3.
Figure 3.3: Ligand interactions map.Interactions with tunicamycin and CbM-
raY active site (PDB ID: 5JNQ) as mapped with the ligand interaction map
(Maestro, Schrödinger). The illustration is adopted from [35].
3.1.2 Enzymatic activity of CbMraY
To investigate the translocase activity of CbMraY, we performed a FRET-
based activity assay on membrane fractions containing overexpressed CbMraY
(Paper I) and determined the initial rate (2.1x104 -∆F520/min; 5µg/ml
total membrane protein concentration) from the single wavelength F520nm
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(instead of the ratio F590/F520) as it follows the direct consumption of
UDP-MurNAc-pentapeptide, illustrated in Figure 3.4.
Figure 3.4: Initial rate determination. Determination of initial rate for wild-
type CbMraY . 5 µg of membrane fractions were used to obtain linear progress
curves for a 30 minutes reaction (A). Initial rates were then calculated from
the first two minutes of the ∆F520nm signal (B).
3.1.3 Mutations to probe the active site
Mutations in the active site of CbMraY aided the investigation and spec-
ulation of specific residues involved in substrate binding or positioning as
summarised in Paper I. Figure 3.5 illustrates the progress curves of the
respective mutant proteins. The residues F228, N172, D175, D178, D231,
H290 and H291 are crucial for MraY translocase activity [92], confirmed
by the low enzymatic activity of D175N, D231A and H290N mutant pro-
teins (Paper I). In contrast to a BsMraY (Bacillus subtilis MraY ) mutant
N221A (Bs numbering) that showed enzymatic activity [92], our mutants
of N221 were almost entirely inactive; thus, N221 is likely involved in
substrate binding in CbMraY.
The phenylalanine F228 is conserved among the PNPT family; mutation
to alanine led to almost complete inactivation of the enzyme, and docking
studies suggest an involvement of this residue in substrate binding (Paper
I). Mutations of D175 resulted in inactive MraY enzyme - D175 is essential
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Figure 3.5: Enzymatic activity of
CbMraY mutant proteins. Progress
curves from the FRET-assay. Con-
centration of membrane fractions
containing overexpressed mutant
proteins were adjusted to obtain
similar progress curves as for the
wild-type protein.
for MraY activity (and conserved in MraYs [92]) as the residue is involved
in uracil binding and potential coordination of a metal ion. Hydrophobic
mutations of D175 destruct MraY activity; substitution to an asparagine
maintained some coordination to the metals but showed reduced affinity
to the metal ions and reduced binding of uracil [36].
3.1.4 Binding modes of the natural product inhibitors
The natural nucleoside antibiotics share a common uridine motif - which
is also present in UDP-MurNAc-pentapeptide - and only tunicamycin and
mureidomycin interact with the residue D231 responsible for Mg2+ bind-
ing, and both inhibitors compete with the magnesium ion, as shown pre-
viously [36, 37]. Analysis of all available complex structures reveal that
the uridine motifs are wedged in the uracil binding pocket with almost en-
tirely overlapping conformations for the inhibitors [37] (see Figure 3.6, the
natural product inhibitors are superimposed in the CbMraY active site).
Interestingly - among the natural nucleoside inhibitors - only tunicamycin
shows cross-reactivity with GPT. Despite similar binding modes of the uri-
dine motifs, the uracil binding pocket allows some degree of flexibility as
highlighted in Paper II and shown in the slightly different binding modes
for capuramycin and 3-hydroxymureidomycin A.
In contrast to the structural similarity of the uridine motifs in the uracil
pocket, the adjacent pocket lined by residues T52, N172, D175, and G230
(AaMraY numbering) allows binding of different motifs, while maintaining
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Figure 3.6: Structures of the MraY nucleoside inhibitors.Comparison of the nu-
cleoside inhibitors in the active site of CbMraY (PDB ID: 5JNQ). Tunicamycin
(orange) is superimposed with the inhibitors: (A) MD2 (PDB ID: 5CKR) (B)
3´-hydroxymureidomycin A (PDB ID: 6OZ6) (C) Carbacaprazamycin (PDB ID:
6OYH) (D) Capuramycin (PDB ID: 6OYZ). Circles in pink highlight the uracil
binding pocket; circles in black the uracil adjacent pocket.
a similar orientation of the active site residues [37]. Compared to the
other nucleoside inhibitors, tunicamycin is missing hydrogen bonds with
the residues of this pocket, but instead forms hydrogens bonds with K111
and backbone interactions with F173.
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3.2 Novel and optimised protocols for purifica-
tion of membrane proteins
Even though we could solve the structure of CbMraY in complex with
tunicamycin, low expression levels and yield and low stability of the purified
protein hampered the ongoing project. To further investigate the binding
of tunicamycin and modified tunicamycins via biophysical techniques, the
existing protocol required optimisation as described in the next section.
3.2.1 Optimisation of CbMraY expression, purification and
crystallisation
Improved protocol for expression and purification To overcome low
yields and low stability of the purified CbMraY, we adjusted the expres-
sion protocol by slowing down expression and delayed the induction via
the addition of glucose to the cultures. This simple alteration led to an
improved yield of correctly inserted membrane protein by a factor of ∼15
compared to the previous protocol. Besides, we modified the purification
protocol, so that no membrane preparation step is required and the mem-
brane proteins are extracted directly from the crude cell lysate with the
detergent DDM that is exchanged during IMAC to DM. The final protocol
provided larger amounts of stable membrane proteins for subsequent use
in biophysical assays such as ITC, which require high amounts of sample
(Paper III).
Crystallisation All available structures of the PNPT superfamily, includ-
ing our in-house structure, are of modest resolution. The solvent content
is high, the crystal packing is poor, and all structures have derived from
vapour diffusion experiments. To improve crystallisation of CbMraY, we
continued working with the same construct and obtained initial crystal
leads in different conditions as shown in Figure 3.8 (no crystals could be
obtained in the original conditions), which are reproducible. Furthermore,
detergent effects [93] may also limit the resolution. For future studies,
we, therefore, would like to perform detergent screens to overcome this
issue. Besides, we attempted to establish a protocol for the crystallisation
of MraY in LCP, but large screens resulted in poorly diffracting hits.
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Figure 3.7: Crystallisation screen of CbMraY.Obtained crystals of CbMraY in
complex with tunicamycin.
Furthermore, for future studies, we would like to design novel CbMraY
constructs aimed at adding a fusion tag (BRIL) on the N-terminus; thereby
increasing opportunities for crystal contact formation.
3.2.2 A new protocol for improved membrane protein pu-
rification using teabags
We chose the teabag system to investigate its value in membrane protein
purification (see detailed description in Paper IV) and [94]. We have
purified different membrane protein targets with the teabags and compared
the samples to the conventionally purified proteins. Briefly, teabags can be
prepared from a nylon mesh using varying sizes and filled with an affinity
resin of choice. After heat-sealing and a washing step, the teabags can be
either stored in ethanol or used directly for protein purification [94].
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Despite advances in the field, membrane protein production and purifi-
cation remain challenging, demonstrated by the underrepresented crystal
structures deposited in the protein database PDB [95]. As described in
Paper IV, our novel method allows purification of membrane proteins
cheaply and easily, with significantly reduced purification time. In our
study, membrane proteins purified with teabags were stable and of high
quality, which we used for subsequent structural and functional studies.
We could demonstrate a better purity and quality of the teabag sam-
ples: in general, elution peaks from the size exclusion profiles appeared
sharper from the teabag samples. Electron microscopy of our test protein
(the chloride ion channel ClC-1) revealed that teabag samples were more
homogenous compared to the conventionally purified protein.
We hypothesised the better quality of the teabag samples derives from
milder purification conditions: no pressure applies on proteins due to the
lack of columns or automated HPLC systems, the shorter purification time
reduces the exposure time to the high concentration of the solubilising
detergent, and the teabag samples might be less delipidated due to the
shorter purification time [96].
The strengths of our study are the use of different membrane proteins -
including pharmacological relevant and challenging targets - covering dif-
ferent expression systems, detergents and IMAC resins. We could demon-
strate that teabag purification significantly reduces the purification time
while allowing the production of pure samples of high quality. The use of
teabag purification may be advantageous for purification of challenging
membrane proteins (Paper IV).
3.3 Cross-reactivity with human GPT
As mentioned in section 1.5, the eukaryotic PNPT family member GPT
is a structural homolog of the bacterial MraYs and targeted by tuni-
camycin. Hence, tunicamycin is toxic to humans and preventing its usage
as an antibiotic. Our complex structure and biophysical characterisation
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of CbMraY and tunicamycin together with the release of the GPT struc-
tures [38,39] enabled a thorough structural comparison with the bacterial
MraYs - leading the way to the rationalised compound design of antibiotics
that selectively target MraY (Paper II and Paper III).
3.3.1 Structural comparison of MraY and GPT
The overall fold of human GPT is similar to MraY and comprises ten
transmembrane helices, with both the N-terminus and C-terminus located
luminal, and four extracellular and five cytosolic loops. Besides the missing
cytosolic doming in MraY, including the βαββ motif, the overall struc-
ture of human GPT appears similar to MraYs with mostly overlapping,
transmembrane helices, including the active site (Figures 3.8 and 3.9).
The cytosolic domain of GPT is protruding into the active site, making it
more restricted. The C-terminal ending of helix 9b is not entirely overlap-
ping with the corresponding helix 9b of MraY, as it is tilting more inwards
so that the ending side chains L293/294 of helix 9 are protruding, pointing
towards the active site. Human GPT provides a complete structure com-
pared to MraY, where missing loops are connecting the transmembrane
helices in MraY - the uridine binding motif / β-hairpin motif is not visible
in the MraY structures [39] (Paper II).
3.3.2 Active site comparison
The active site of GPT appears more narrow and closed up compared
to CbMraY. It is worth to mention that a comparison of the active sites
could result in a somewhat misleading picture of the MraY active site - not
all loops were modelled to due poor resolution. Helix 9c - lined by loops
5-6, 7-8 and helices 5-10 - and the additional cytosolic domain form the
cytoplasmic cleft. The uracil binding pocket is slightly bigger in GPT. Due
to changes in the 9b-c stretch, the additional loop is protruding towards
the active site; making it more narrow and less accessible than the shallow
active site in CbMraY. The C-terminal ending of helix 9b is slightly tilted
compared to CbMraY so that the ending residues are protruding towards
the active site. This region is the cavity for the fatty acyl chain of the
substrate and tunicamycin. In the GPT-tunicamycin complex structure
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Figure 3.8: Structural comparison of GPT and MraY. (A) The
CbMraY(white)-tunicamycin complex (PDB ID: 5JNQ) superimposed with the
human GPT(cyan)-tunicamycin complex (PDB ID: 6BW5). Orientation within
the lipid membrane is indicated by dashed lines. The figure is modified from [90]
(B) Acite site view in surface respresentation of GPT with the bound inhibitor
tunicamycin (yellow). Transparency of the surface visualizes tunicamycin is en-
closed in the GPT active site.
and the residues W122, H302 and R301 (all GPT numbering) are flipping
down locking the bound tunicamycin in place. The movement of W122
creates a narrow tunnel to position the fatty acyl chain of tunicamycin.
The movement of the sidechains H302 and R301 closes the cavity in which
the nucleoside is bound to even tighter. Figure 3.9 illustrates interactions
with tunicamycin [39] (Paper II).
The following paragraph discusses the use of ligand docking to analyse
the interactions of human GPT and tunicamycin, which we conducted
before the release of the GPT-tunicamycin complex [39] (see section 2.3
for experimental design of the docking). Figure 3.9 shows an alignment
of the active sites of the docked complex and the published GPT-complex
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structure: we determined likely interactions of tunicamycin with human
GPT with the best docking pose (most similar to the tunicamycin confor-
mation in the CbMraY structure) including the residues R301, H302 and
R303 (GPT numbering), which are essential for GPT activity [91]. The
Figure 3.9: GPT active site interactions.(A) Active site comparison of CbM-
raY (blue)–tunicamycin (yellow) complex (PDB ID: 5JNQ) superimposed with
the GPT (white)– tunicamycin (green) complex (PDB ID: 6BW5). Residues
that interact with the ligands are shown as sticks (GPT numbering). (B) Com-
parison of the docked pose of GPT (not visualised) and tunicamycin (green)
superimposed with the GPT (white)-tunicamycin (yellow) complex (PDB ID:
6BW5).
docking proposed interaction with L293 pointing towards the GPT active
site - which is missing in MraY - and the stacking with F249 in the uracil
binding pocket. The docking suggested more direct interactions with tu-
nicamycin compared to the CbMraY structure, which is in agreement with
the published structure [39]. Despite the docking was performed with an
apo structure, and tunicamycin being a problematic compound to use
in docking due to flexibility of the ligand structure, the experiment was
successful.
The resulting pose was similar to the crystal structure and predicted
most interactions of the active site residues with tunicamycin. The use of
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ligand docking is therefore recommended in cases where a 3D structure is
missing. It is worth to mention that the docking was successful since the
apo and GPT complex structures show a high similarity and the complex
structure of MraY with tunicamycin was available to aid in the assignment
of the docking poses.
3.3.3 Comparison of tunicamycin interactions
In GPT, both the uracil and the ribose ring position in a small cavity
where the two of them form interactions with side chains of the active
site, and the pocket appears more prominent than in MraY. In CbMraY,
only the uracil ring interacts with the active site residues. Modifications of
the ribose ring could lower the affinity for GPT, but the affinity for MraY
may be unaltered.
The 6-bis-hydroxyl group of GlcNAc forms no interactions with GPT,
whereas it interacts with F173 in MraY. Therefore, removing the 6-bis -
hydroxyl group, as in QVM (Paper III), could lower the affinity for MraY,
but it should not affect the affinity for GPT - as confirmed in Paper III
and [53].
In contrast to MraY, both the 3-bis-hydroxyl and the N-acetyl group
interact with R303 in GPT. Modifications of this motif in tunicamycin
would probably show no effect in MraY but may lower the affinity for
GPT. Residue R301 coordinates the oxygen in the tunicamine sugar ring
in GPT. In contrast, this oxygen is not involved in interactions with the
MraY active site amino acids. Modifications at this part of the tunicamine
- to disrupt interactions with R301 - could lower the affinity for GPT,
whereas the affinity for MraY may remain unaltered. In contrast to MraY,
no interactions with the 5’-hydroxyl group in GPT are present due to the
lack of a corresponding aspartic acid in this region of GPT.
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3.4 Biophysical characterisation of tunicamycin
binding
In this project, a competitive 1D-NMR binding assay led to the first inves-
tigation of the direct binding of tunicamycin to purified CbMraY wild-type
protein using UMP as a weak inhibitor. Figure 3.10 shows the setup of the
experiment: The experiment is initiated with the inhibitor UMP in assay
buffer. Addition of purified CbMraY leads to binding of UMP to MraY
that is competed out by addition of tunicamycin in a following step. De-
spite the success of this experiment, we decided to determine the binding
constant KD with alternative methods, as the difference in potency be-
tween tunicamycin and UMP was expected to be too large for an accurate
determination of the dissociation constant. This assumption may be false
due to our inhibition measurements with UMP and MraY (IC50: 20000
nM) as described in the following paragraph.
Further investigation of the inhibition of CbMraY with the FRET-assay
allowed determination of the IC50 for tunicamycin (391nM, Figure 3.11),
reflecting the inhibitory effect on MraY present in membranes and not
purified protein, which is in agreement with previous studies performed
with AaMraY (450nM IC50, [39]). We performed ITC experiments to de-
termine the KD value (233nM), which was in the same range as in studies
performed with AaMraY [39]. Used as a control compound, UMP showed
inhibitory effect on CbMraY with an IC50 of 19.500nM.
3.4.1 Modified tunicamycin analogues and their binding
to MraY
In order to find potent and selective MraY inhibitors, we investigated
structural motifs of modified and purified tunicamycins to rationalise in-
hibitory effects as determined by half-maximal inhibitory concentrations
(IC50), binding affinities and thermal stabilities (Paper III). To do so, we
have altered four parts of the tunicamycin motif: the length and branching
of the fatty acyl chain, the saturation of the fatty acyl chain, the 6-bis-
hydroxyl group of the GlcNAc ring, and the ring structure of the uracil
motif.
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Figure 3.10: Tunicamycin binding to CbMraY by 1D NMR.Competitive ligand
binding with tunicamycin and UMP. 1, the upper trace used as a reference step
to rule out that UMP does not form interactions with detergent micelles; 2, the
next lower trace visualises UMP binding to CbMraY, which is competed out in
the next step (3) by addition of tunicamycin. The lower trace (4) illustrates a
UMP reference spectrum.
Tunicamycin consists of different variants where the end of the fatty
acyl chain occurs in different configurations including iso (CH3CH(CH3)-),
anteiso (CH3CH2CH(CH3)-) and unbranched (CH3CH2-) [97], and can
vary in length (illustrated in Figure 3.12). A purified tunicamycin anteiso
analog has not been observed and reported before, but has been reported
for streptovirudins and corynetoxins [52]. We investigated the inhibitory
effect for purified tunicamycins with varying chain lengths (Tun14:1-17:1).
Our findings demonstrate a high potency for the shorter chain length
compounds with an optimal chain length of 15:1(iso) followed by 16:1(iso)
and 17:1(iso) (Figure 3.13). Interestingly, Tun14:1(iso) showed reduced
potency, lower than 17:1(iso).
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Figure 3.11: Inhibitory effect of tunicamycin. IC50 plots showing the inhibitory
effect of tunicamycin and UMP.
Also, the branching type had an impact on inhibition and potency, as
shown by the increased values by approximately 8-fold of the anteiso com-
pounds compared to their iso branching counterparts. Figure 3.13 shows
IC50 plots, ITC binding isothermals and melting curves. It is worth to
mention that we observed the same potency trend in all assays. The loca-
tion of the branching seems to impact the inhibitory effect against MraY,
demonstrating the importance to have maximal interactions between the
inhibitor and the active site residues.
Reasoning, how the branching and the length of the fatty acyl chain
impact inhibition and potency towards MraY, is hampered by the lack of
electron density in the MraY structures. Both the CbMraY-tunicamycin
complex and the MraY-carbacaprazamycin complex show poor density for
the fatty acyl chain; thus rationalisation of the branching position based
on the structures could be problematic. Nevertheless, an inspection of the
carbacaprazamycin fatty acyl chain opens up room for speculations: we
have superimposed the MraY-carbacaprazamycin complex and the GPT-
tunicamycin complex (PDB ID: 6BW5) in the active site of CbMraY. A
phenylalanine F162 in the hydrophobic tunnel would prevent tunicamycin
from binding to MraY similarly as in GPT so that the fatty acyl chain
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Figure 3.12: Chemical structure of modified tunicamycins.The modifcations
are illustrated in comparison to the core structure of tunicamycin. TunR1,
TunR2 and TunR3 are a mixture of the N-acyl variants C-14, C-15, C-16 and
C-17. QVM is a purified analog of the N-acyl variant C-16.
is forced to make a bend as seen for carbacaprazamycin, where the bent
chain is leading towards a restricted pocket (Figure 3.14). In this case, a
Tun 14:1 (iso) may be somewhat sterically hindered by F162, in contrast
to a Tun 15:1 (iso) having more space in the cavity of the hydrophobic
pocket of MraY. The longer chain analogues Tun 16:1 (iso) and Tun 17:1
(iso) may be positioned too close to the restricted pocket and F162 in
comparison to Tun 15:1 (iso). According to this reasoning, Tun 15:1 (iso)
may fit in the best pose with the fewest steric clashes. Figure 3.14 further
illustrates the possible positioning of the Tun 15:1 (anteiso) analogue,
where a clash or steric hindrance may occur due to proximity to F162, and
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Figure 3.13: Effects of tunicamycin analogs on CbMraY activity and sta-
bility.(A) Inhibitory effects of the analogs on CbMraY enzymatic activity as
determined by the FRET assay. (B) Effects on thermal stability of CbMraY by
the tunicamycin analogs. (C) Dose-response curves from the FRET assay. (D)
ITC titration, fitted curves of tunicamycin analogs. Inhibitors were titrated to
purified CbMraY protein in the absence of MgCl2.
Tun 17:1 (anteiso) possibly being positioned too close to the restricted
pocket and F162. This reasoning may explain the lower potency of the
anteiso analogues compared to their iso counterparts.
The purified tunicamycin (iso) analogues showed a higher potency and
inhibition compared to commercial tunicamycin. To rationalise this dis-
crepancy, we analysed the commercial tunicamycin sample with 1D NMR
to determine the branching types of the acyl chains present in the mixture
of homologues. The sample contained iso branching analogues as major
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Figure 3.14: Potency of the acyl chain analogues.Comparison of acyl chains of
capacrapazamycin (PDB ID 6OYH, blue) and tunicamycin (PDB ID: 6BW5,
orange). The two compounds are superimposed in the active site of CbMraY.
Numbering of the chain from C-11 to C-15 is highlighted for cabacrapazamycin
and red arrows at positions C-12 and C-13 indicate the possible position of the
methyl groups for a 14(iso) and 15(iso). F162 is highlighted in red.
component, and a minor fraction of anteiso analogues was present as well.
We could not detect an unbranched variant.
TunR1 contains a saturated C2-C3 bond in the fatty acyl chain (Figure
3.12) and showed unaltered inhibitory effect, binding affinity and stabilis-
ing effect compared to tunicamycin - suggesting the hydrophobic tunnel
in MraY being more adaptable to changes in the C2-C3 bond of the fatty
acyl chain. In contrast, GPT contains a more enclosed hydrophobic tun-
nel, including a tryptophane W122, which locks the lipid tail in place.
Thus, GPT is likely more sensitive to alterations in the C2-C3 bond - in
agreement with recent studies showing similar inhibition of tunicamycin
and TunR1, whereas TunR1 showed reduced inhibition towards S. cere-
visiae [48].
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We investigated the effect of a reduced uracil ring in the modified
tunicamycin TunR2, which showed a minor reduction in inhibitory effect
and binding affinity by a factor of approximately 1.5-2.0. The uracil group
of tunicamycin wedges in a well-defined pocket, where a phenylalanine
F228 (conserved in MraYs and GPT) stacks against the uracil ring. Hence,
reducing the double bond of the uracil ring likely disrupts the planarity of
the uracil ring and influences the pi-pi stacking. The impact on the potency
by alteration of the uracil ring was neglectable, which is in agreement with
previous studies of streptovirudins [52]. In contrast, TunR2 showed a more
reduced potency towards GPT [48,49], where the uracil binding pocket is
more rigid compared to MraY.
Investigation of the modified tunicamycin TunR3 (with an open uracil
ring motif) revealed a significantly reduced inhibitory effect and bind-
ing affinity compared to tunicamycin, which is in agreement with pre-
vious studies demonstrating that TunR3 had no inhibitory effect on N-
glycosylation [50]. In TunR3, the open uracil ring structure likely disrupts
major interactions with the uracil binding pocket that occur with the
closed uracil ring motif, but must still enable some interactions with the
uracil binding pocket. Previous studies found the uracil motif required for
inhibition of a modified tunicamycin, where removal of the uracil motif
prevented the compound from inhibiting MraY [98].
In the CbMraY structure, the 6´´-hydroxyl group of tunicamycin forms
interactions with the backbone of F173 and with the side chain of H290.
The missing 6´´-hydroxyl group in QVM likely disrupts these interactions
- in agreement with our findings, which revealed a dramatically reduced in-
hibitory effect and binding affinity of QVM16:1(iso); the IC50 and KD val-
ues were approximately 150 times reduced compared to the Tun16:1(iso)
analogue. The 6´´-hydroxyl group has a more significant impact on in-
hibition of MraY compared to GPT as shown by studies demonstrating
similar minimum inhibitory concentration (MIC) values of QVM and tu-
nicamycin against S. cerevisiae. In contrast, tunicamycin is tenfold more
potent than QVM against Bacillus subtilis bacteria [53]. This observation
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can be explained by the complex structure of GPT and tunicamycin, re-
vealing no interaction of the 6´´-hydroxyl group in tunicamycin and the
active site residues of GPT. Furthermore, this is likely the only interaction
between the GlcNAc motif and the MraY active site (Paper I and Paper
II), and disruption of this interaction causes dramatic inhibitory changes.
This notion is in agreement with a recent study, where the entire GlcNAc
motif was removed, resulting in a similar inhibitory effect as QVM in our
study [98].
3.5 Rationalisation of selective MraY inhibitors
The release of our CbMraY-tunicamycin complex, followed by the GPT
crystal structures [38, 39] led the way to a rationalised approach for the
design of selective MraY inhibitors. Despite the similar overall structure,
the active site of human GPT shows some distinct differences upon thor-
ough analysis. The most noticeable difference is the enclosed active site
of GPT with a more restricted entrance compared to MraY. This simple
fact most likely prevents large or rigid compounds from binding effectively
to GPT. Furthermore, the overall structure of GPT appears more rigid
and ordered, with only minor conformational changes of some active site
residues upon ligand binding [39]. Tunicamycin is, therefore, a more po-
tent inhibitor of GPT than MraY (in agreement with published IC50 and
KD values: [39]; Paper III), and GPT is likely more sensitive to modifica-
tions in the binding motifs of the inhibitors. This notion is in contrast to
MraY, showing a disordered active site in the apo structure compared to
the complex structures - possibly allowing more flexibility to compound
binding, as demonstrated in the recently published complex structures (de-
scribed in section 3.1 and [37]). It is worth to mention that studies suggest
a possible complex formation of MraY with the membrane-associated pro-
tein MurG [99]. Such a potential complex might change the active site of
MraY dramatically, possibly making it more enclosed, similar to GPT.
We found a region of interest in the MraY structure upon reasoning why
the natural product antibiotic MD2 is selectively targeting MraY and not
GPT. Our structural alignment (Paper II) revealed a major clash between
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the peptidic moiety of MD2 and the additional cytosolic domain TM9b-
TM10; thus preventing MD2 from binding effectively to GPT. This notion
is in agreement with a recent study, where substitution of the MurNAc
sugar by a GlcNAc sugar reduced the inhibitory effect of a modified tuni-
camycin analogue towards GPT - rationalised by the active site and sugar
substrate differences of MraY and GPT [39].
Observation of the hydrophobic tunnel in the GPT active site pinpoints
another region of interest: the hydrophobic tunnel is tighter compared to in
MraY, containing W122 (GPT numbering), which locks the lipid tail of the
substrate and tunicamycin in place. In Paper III we rationalised that due
to the restricted tunnel in GPT, alteration of the C2-C3 bond in the fatty
acyl chain of tunicamycin has a more significant impact on GPT inhibition
without affecting the potency towards MraY. Recent studies picked up on
this notion and introduced a second acyl chain to the tunicamycin motif,
resulting in a selectively potent compound, which cannot inhibit GPT [38].
Very recently, Lee and coworkers [37] highlighted the binding pocket
formed by residues T52, N172, D175, and G230 (AaMraY numbering) -
adjacent to the uracil binding pocket - as an exciting site to investigate for
selective MraY inhibitors. A corresponding binding pocket is missing in the
GPT structure, and it allows binding to a variety of structural motifs (see
Figure 3.6). This region in the MraY active site is not a required motif for
inhibition but can alter the potency without facing cross-reactivity issues
with GPT [37], which is in agreement with previous SAR studies [100,101].
Finally, the uracil binding pocket reveals another region of interest as
the pocket appears more well-defined in MraY compared to in GPT. Re-
duction of the uracil ring in tunicamycin only showed a minor impact on
MraY inhibition, whereas potency towards GPT seems to be altered more
pronounced, as demonstrated by cell toxicity assays [48]. TunR2 is, there-
fore, a promising starting compound for the design of selective tunicamycin
inhibitors. The following alterations could optimise TunR2 towards a se-
lective MraY inhibitor: use of the higher potency for the shorter chain
length tunicamycins, where a TunR2 15:1(iso) should hypothetically be
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most potent towards MraY and at the same time further reduce the po-
tency towards GPT; and secondly, reduction of the C2-C3 bond of the
acyl chain could further reduce GPT inhibition.
55

Chapter 4
Concluding remarks
Antibiotic resistance is rapidly growing and considered one of the biggest
threats to human health. It is of utmost importance to design and develop
novel antibacterial agents in order to slow down antibiotic resistance. The
work performed in this thesis involves the structural and functional studies
of the antibacterial target MraY with different inhibitors for the future
design of antibacterial drugs.
We present the crystal structure of MraY from the pathogen Clostrid-
ium bolteae in complex with the natural nucleoside inhibitor tunicamycin
in Paper I. The structure together with functional and biophysical studies
of active site mutant proteins provided the detailed binding mode of tuni-
camycin and substrate binding. Both AaMraY and CbMraY were shown
to crystallise as dimers. However, the impact of the oligomeric status on
MraY activity remains unclear. Electron density for AaMraY indicated the
positioning of lipid molecules in the hydrophic tunnel of the dimerisation
interface [34]. Furthermore, MraY enzymatic activity and functional fold-
ing was depending on anionic charged lipids and the absence of detergents
in the Gram-negative homologues, whereas lipids were nonessential for ac-
tivity of the Gram-positive BsMraY homologue that tolerated the presence
of detergents [102]. This might indicate that the oligomeric status and
its impact on MraY activity is different between the Gram-positive and
Gram-negative homologues and would be an interesting topic for future
investigations.
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Our structural comparison between MraY and its human homologue
GPT is presented in Paper II, where we highlight regions of interest for
modifications of tunicamycin to selectively target MraY.
We have modified and purified tunicamycins and investigated their po-
tential for MraY inhibition and potency. Our results, presented in Paper
III, identified potent MraY inhibitors with reduced toxicity in eukaryotes
that may be used for the future design of novel antibacterial drugs. Future
studies with GPT and our selected compounds should be performed to ex-
amine their inhibitory effect and potency. To investigate the difference in
potency and inhibition between the iso and anteiso branched tunicamycins,
future studies should aim to crystallise MraY in complex with the different
branching variants of tunicamycin.
In Paper IV, we have applied the novel teabag method to investigate
its use in membrane protein purification. We found that our novel method
significantly reduced the purification time, while producing stable and pure
proteins that were used for subsequent functional and structural studies.
The quality and purity of the teabag samples were identical - or in some
cases exceeding - compared to the conventional method. We speculated
the exceeding quality of the teabag samples might be related to the shorter
purification time resulting in less delipidated samples due to the slow
kinetics of delipidation [96], which should be investigated in future studies.
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